This antibody is specific to IKB alpha/IKBA (Sumoylation Site).
Purification
Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Immunogène
This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human IKB-alpha around the sumoylation site.
NFKBIA
Reactivité: Humain, Souris, Rat
WB, ELISA
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
ELISA: 1/1,000. Western Blot: 1/100-1/500. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Format
Liquid
Concentration
0.25 mg/mL
Buffer
PBS with 0.09 % (W/V) Sodium Azide as preservative.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Conseil sur la manipulation
Avoid repeated freezing and thawing.
Stock
4 °C/-20 °C
Stockage commentaire
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Antigène
NFKBIA
(Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, alpha (NFKBIA))
NFKB1 or NFKB2 is bound to REL, RELA, or RELB to form the NFKB complex. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA or NFKBIB), which inactivate NF-kappa-B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, or IKBKB) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T, R is an A or G purine, and Y is a C or T pyrimidine).Synonyms: I kappa B-alpha, I-kappa-B-alpha, IkB-alpha, IkappaBalpha, MAD3, Major histocompatibility complex enhancer-binding protein MAD3, NF-kappa-B inhibitor alpha, NFKBI